GlassScriptPhysician profile
Steven A Norris
NPI 1205877206
$3,892.32
in general payments reported to CMS, 2019-2025
27 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $545 · 2021: $603 · 2022: $425 · 2023: $450 · 2024: $336 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.57 | 2021-2025 | |
| Amgen INC. | $557.49 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $542.97 | 2019-2025 | Ajovy |
| Lilly USA, LLC | $427.81 | 2019-2025 | Kisunla, Emgality |
| Acorda Therapeutics, INC | $196.90 | 2019-2024 | Inbrija |
| Pfizer INC. | $186.98 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $129.23 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $127.46 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $123.80 | 2021-2024 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $117.95 | 2021 | |
| Jazz Pharmaceuticals INC. | $106.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $93.66 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $89.69 | 2020-2021 | |
| Allergan, INC. | $87.50 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $72.35 | 2022-2024 | Nuplazid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $64.41 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $58.35 | 2022-2025 | Givlaari |
| Biohaven Pharmaceutical Holding Company LTD. | $55.94 | 2022 | |
| Janssen Pharmaceuticals, INC | $55.15 | 2019 | |
| Azurity Pharmaceuticals, INC. | $47.21 | 2024-2025 | Horizant |
| Kyowa Kirin, INC. | $27.68 | 2024 | Nourianz |
| Zyla Life Sciences, INC. | $24.20 | 2019 | |
| Axsome Therapeutics, INC. | $24.13 | 2025 | Symbravo |
| Biogen, INC. | $23.53 | 2021 | |
| Almatica Pharma LLC | $22.89 | 2021 | |
| Ge Healthcare | $22.75 | 2019 | |
| Mdd US Operations, LLC | $21.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Norris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.